Back to search results

Geriatric Assessment for Older Adults with Non-Small Cell Lung Cancer

This study is looking at how a special health check-up for older adults, called a geriatric assessment (GA), can help patients aged 60 and over with unresectable (meaning it can't be removed by surgery) non-small cell lung cancer (NSCLC) who are receiving chemotherapy and radiation. Researchers want to see if providing doctors with a summary of your GA and recommendations based on it can reduce serious side effects (grade 3-5 non-hematologic toxicities) from treatment, compared to receiving usual care. The study also aims to see if this approach improves your quality of life and reduces functional decline. The study plans to enroll 180 participants, but its current status is unclear.

Study design
This interventional study plans to enroll 180 participants. It compares two approaches: usual care versus a geriatric assessment with specific recommendations for your care team.
What's involved
You would undergo blood and stool sample collection, complete a comprehensive geriatric assessment, and have your electronic health records reviewed. The primary outcome is measured at 6 months from treatment initiation.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at 6 months from treatment initiation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06139627

Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy

Recruiting
NAAges 60+InterventionalSupportive care
City of Hope Medical Center
~180 participants
Updated 2026-07-08 on ClinicalTrials.gov
What's tested:Best PracticeBiospecimen CollectionCommunication InterventionComprehensive Geriatric AssessmentElectronic Health Record ReviewSurvey Administration

At a glance

Recruiting sites
2 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of grade 3-5 non-hematologic toxicities
Measured over At 6 months from treatment initiation

Conditions

Lung Non-Small Cell Carcinoma
Stage III Lung Cancer AJCC v8

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

3 sites across 3 states
California1
New York1
Ohio1

Study leadership

  • Arya Amini · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Arya Amini
[email protected]
626-256-4673 · ext. 82247
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

ONCOLOGY PHYSICIANS INCLUSION:
Oncology physicians must work at the participating site with no plans to leave that site or retire at the time of enrollment into the study
PATIENTS INCLUSION:
Any patient with unresectable non-small cell lung cancer diagnosis who is 60 years of age or older and must be treated at the participating site
Clinical staging without pathological confirmation of nodal disease is allowed
Plan to start a new cancer treatment regimen within 4-6 weeks from time of baseline study visit. The treatment regimen is up to the discretion of the treating oncology physician. The regimen must include a chemotherapy drug or other agents that have similar prevalence of toxicity. This can be either concurrent or sequential with radiation therapy
Chemotherapy will be defined as cytotoxic drugs; in addition, agents (e.g., monoclonal antibodies and targeted agents) will be allowed. Given the rapidly changing landscape of new drugs for cancer, the study team led by the principal investigator (PI) will update the list accordingly after reviewing the toxicity profile of new therapies
Patients who are receiving approved cancer treatment in combination or sequentially with radiation including hypo fractionated radiation (45-60Gy in 15-20 fractions) are eligible
Those patients with oligometastatic disease having only one site and one lesion outside of the radiation field will be eligible. Examples include a solitary brain metastasis (met), contralateral lung nodule or an adrenal metastatic site
Able to provide informed consent, or if the oncology physician determines the patient to not have decision-making capacity, a patient-designated health care proxy (or authorized representative per institutional policies) must sign consent by the baseline visit
Participant or healthcare proxy has adequate understanding of the English language (preferred) because not all GA measures have been validated in other languages. Study team should be contacted for any participants with other preferred languages including Spanish and Mandarin. Inclusion of these participants will depend upon the availability of the translators and their ability to accurately translate the measures as approved by the local Institutional Review Board (IRB)

Exclusion

PATIENTS EXCLUSION:
Have surgery planned within 3 months of approach date. Patients who have previously received surgery are eligible
Presence of symptomatic brain metastases (if more than one) at time of study consent process. Patients with history of treated brain metastases or small indeterminate lesions (\< 1cm) are eligible if they are not symptomatic at the time of study enrollment
More than one metastatic site: Examples: brain and adrenal, adrenal and liver

What this trial measures

  • Incidence of grade 3-5 non-hematologic toxicitiesAt 6 months from treatment initiation

    Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0) for grade 3-5 non-hematologic toxicities. Chi-square test will be used to compare proportion of patients with grade 3-5 non-hematologic toxicity between two arms at 6 months after treatment initiation.